Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hematologic Neoplasms × fedratinib × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Primary Myelofibrosis 2 Myeloproliferative Disorders 2 Hematologic Neoplasms 1

Interventions

Olanzapine 4 Cyclophosphamide 4 Voriconazole 3 Tranexamic Acid 3 Standard of Care 3 letermovir 2 fludarabine phosphate 2 Zoledronic Acid 2 Whole-Body Irradiation 2 Practice Guidelines as Topic 2 Peripheral Blood Stem Cell Transplantation 2 Mycophenolic Acid 2 Methods 2 Educational Status 2 Early Intervention, Educational 2 Doxorubicin 2 Cyclosporins 2 Cyclosporine 2 trihexyltetradecylphosphonium chloride 1 thymoglobulin 1 shengxuening 1 posaconazole 1 pembrolizumab 1 olaparib 1 nilotinib 1 lenvatinib 1 ferrous succinate 1 fedratinib 1 cilgavimab and tixagevimab drug combination 1 apixaban 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01437787 2025-03-05

JAKARTA

Bristol-Myers Squibb

Phase 3 Completed

289 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡